Brief Summary and Purpose of the Study

This Phase III, open-label, single-arm, single-centre clinical study demonstrated that the combination therapy of Boswellia Curcumin and Joint Aid Plus is a safe, well-tolerated, and effective intervention for the management of knee osteoarthritis–associated joint pain in adult participants over a 90-day treatment period. The study successfully met its primary efficacy objective, with the total WOMAC score showing a consistent and clinically meaningful reduction from Baseline to Day 90, indicating significant improvement in pain, stiffness, and physical function. The progressive decline in WOMAC scores across all visits reflects sustained symptomatic relief and enhanced joint mobility among participants. Secondary efficacy outcomes further supported the therapeutic benefit of the intervention. Participants demonstrated a notable reduction in joint pain intensity, as evidenced by the decrease in VAS scores over time. Additionally, a significant improvement in quality of life, as measured by the SF-36 questionnaire, was observed, indicating enhanced physical well-being, functional capacity, and overall health perception. High subject satisfaction scores further reinforce the positive clinical response and acceptability of the treatment. From a safety perspective, the combination therapy exhibited a favourable tolerability profile throughout the study duration. No serious adverse events (SAEs) were reported. All observed adverse events, including mild dizziness, headache, and nausea, were transient, non-serious in nature, and resolved without medical intervention. Furthermore, vital signs and physical examination findings remained stable, with no clinically significant changes observed, supporting the systemic safety of the intervention. High treatment compliance and the absence of major safety concerns further strengthen the reliability of the study outcomes. In summary, the findings of this study indicate that the combination of Boswellia Curcumin and Joint Aid Plus provides clinically meaningful improvements in osteoarthritis symptoms, pain reduction, and quality of life, while maintaining an excellent safety and tolerability profile. These results support its potential as an effective therapeutic option for the management of knee osteoarthritis. However, given the open-label and single-arm design, further randomized, controlled, and long-term studies are recommended to confirm these findings and to establish the comparative efficacy and durability of treatment outcomes.